ArticleOncotarget2016
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations.
Brendon Ladd et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
20 papers cite it
this papertrialcites it